GlassScriptPhysician profile
William R Weaver
NPI 1679557805
$3,624.33
in general payments reported to CMS, 2019-2025
30 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $641 · 2021: $485 · 2022: $570 · 2023: $595 · 2024: $265 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,096.30 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $332.13 | 2019-2023 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $290.96 | 2019-2024 | Farxiga |
| Pfizer INC. | $282.54 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $207.90 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.83 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $135.52 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $107.29 | 2021-2022 | |
| Glaxosmithkline, LLC. | $91.11 | 2019-2023 | Menveo, Bexsero, Shingrix |
| Merck Sharp & Dohme LLC | $87.02 | 2019-2025 | Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $79.76 | 2019-2022 | |
| Lilly USA, LLC | $79.50 | 2019-2024 | Jardiance, Mounjaro |
| Eisai INC. | $65.83 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $62.44 | 2021-2022 | |
| Amarin Pharma, INC. | $62.10 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $59.43 | 2020 | |
| Intuitive Surgical, INC. | $56.50 | 2019 | |
| Xeris Pharmaceuticals, INC. | $52.33 | 2023-2025 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $51.35 | 2023-2024 | Gemtesa |
| Abbvie INC. | $35.29 | 2023-2025 | Ubrelvy, Synthroid |
| Exact Sciences Corporation | $32.13 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $26.83 | 2020-2022 | |
| Baxter Healthcare | $26.66 | 2022 | |
| Daiichi Sankyo INC. | $24.54 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.45 | 2020 | |
| Idorsia Pharmaceuticals US INC | $23.90 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $13.29 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.02 | 2023 | Rexulti |
| W. L. Gore & Associates, INC. | $11.57 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.